Autologous graft-versus-host disease after denileukin diftitox and autologous stem cell transplantation for refractory T-cell lymphoma.
Zalom
Martina
M
Department of Internal Medicine, Cedars-Sinai Med Ctr, Los Angeles, CA, USA. martina.zalom@cshs.org
Lill
Michael
M
Lukic
Dusan
D
Balzer
Bonnie L
BL
Lim
Stephen
S
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001706:Biopsy; D003131:Combined Modality Therapy; D004167:Diphtheria Toxin / Q000627:therapeutic use*; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology*; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology / Q000601:surgery*; D008875:Middle Aged; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous / Q000276:immunology
D000970:Antineoplastic Agents; D004167:Diphtheria Toxin; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox